article thumbnail

Petitioner Failed to Establish Standing in IPR Appeal

Intellectual Property Law Blog

Furthermore, the Federal Circuit found the declaration was conclusory and failed to establish that Allgenesis had any concrete plans to develop and bring to market a nintedanib treatment for pterygium. Accordingly, the Federal Circuit concluded that Allgenesis failed to show an injury in fact based on potential infringement liability.

Marketing 162
article thumbnail

Biosimilar Maker Leverages IPR to Avoid Patent Dance and Obtain Early Market Entry

Bio Law Blog

settled three Inter Partes Review (IPR) proceedings concerning patents covering Alexion’s blockbuster humanized monoclonal antibody drug Soliris®, with Amgen obtaining a royalty-free license for marketing a biosimilar prior to expiration of the patents at issue. and Alexion Pharmaceuticals Inc. an eculizumab product.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

[GuestPost] Opinion: Patent trolling threatens the market of taxi aggregators in Kazakhstan

The IPKat

These two largest services merged their platforms a couple of years ago, which influenced the taxi market in Russia, Armenia, Belarus, Kazakhstan and several other Commonwealth of Independent States countries. These mobile services have significantly expanded the market, transferring most of Kazakhstanis from public transport to taxis.

article thumbnail

Special 301 Report 2023: Reflections from Public Health Perspective

SpicyIP

Prime Concerns: Observations on Section 3(d) and Oppositions Special 301 report shows particular concern about Section 3(d) of the Patents Act, 1970 because it allegedly restricts “patent-eligible subject matter” to get a patent in contravention of Article 27 of the TRIPS (p. 56, para 3). 59, para 1). 56, para 3).

Reporting 137
article thumbnail

Proactive Strategies in IPRs after Allgenesis

IP Tech Blog

Cloudbreak Therapeutics, LLC , provides some interesting insights into patent challenge strategies, and their consequences, when a potentially infringing product is not yet on the market. An Allgenesis executive testified by declaration that the parties were unable to reach a settlement.

article thumbnail

Proactive Strategies in IPRs after Allgenesis

LexBlog IP

Cloudbreak Therapeutics, LLC , provides some interesting insights into patent challenge strategies, and their consequences, when a potentially infringing product is not yet on the market. An Allgenesis executive testified by declaration that the parties were unable to reach a settlement.

article thumbnail

The Seventh Circuit Affirms Dismissal of the HUMIRA Antitrust Litigation

LexBlog IP

created a “patent thicket” around HUMIRA to block biosimilars from entering the market and entered into “reverse payment” settlement agreements with biosimilar applicants to further delay entry. market until 2023.” ” But the panel noted that, taking the U.S.